- Home
- STTK vs SHMD Comparison
STTK vs SHMD Comparison
Compare STTK & SHMD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- STTK
- SHMD
- Stock Information
- Founded
- STTK 2016
- SHMD 1864
- Country
- STTK United States
- SHMD Germany
- Employees
- STTK N/A
- SHMD N/A
- Industry
- STTK Biotechnology: Pharmaceutical Preparations
- SHMD
- Sector
- STTK Health Care
- SHMD
- Exchange
- STTK Nasdaq
- SHMD Nasdaq
- Market Cap
- STTK 112.6M
- SHMD 179.1M
- IPO Year
- STTK 2020
- SHMD N/A
- Fundamental
- Price
- STTK $1.95
- SHMD $3.91
- Analyst Decision
- STTK Hold
- SHMD
- Analyst Count
- STTK 5
- SHMD 0
- Target Price
- STTK $3.00
- SHMD N/A
- AVG Volume (30 Days)
- STTK 393.6K
- SHMD 575.0K
- Earning Date
- STTK 11-13-2025
- SHMD 01-01-0001
- Dividend Yield
- STTK N/A
- SHMD N/A
- EPS Growth
- STTK N/A
- SHMD N/A
- EPS
- STTK N/A
- SHMD N/A
- Revenue
- STTK $2,997,000.00
- SHMD $85,165,542.00
- Revenue This Year
- STTK N/A
- SHMD N/A
- Revenue Next Year
- STTK N/A
- SHMD N/A
- P/E Ratio
- STTK N/A
- SHMD N/A
- Revenue Growth
- STTK N/A
- SHMD N/A
- 52 Week Low
- STTK $0.69
- SHMD $1.86
- 52 Week High
- STTK $2.71
- SHMD $4.69
- Technical
- Relative Strength Index (RSI)
- STTK 47.89
- SHMD 59.36
- Support Level
- STTK $1.78
- SHMD $3.45
- Resistance Level
- STTK $2.14
- SHMD $4.25
- Average True Range (ATR)
- STTK 0.19
- SHMD 0.60
- MACD
- STTK -0.04
- SHMD 0.05
- Stochastic Oscillator
- STTK 23.41
- SHMD 61.68
About STTK Shattuck Labs Inc.
Shattuck Labs Inc is a biotechnology company specializing in the development of potential treatments for inflammatory and immune-mediated diseases. It is developing a potentially first-in-class antibody for the treatment of inflammatory bowel disease (IBD) and other inflammatory and immune-mediated diseases. The company's expertise in protein engineering and the development of novel tumor necrosis factor (TNF) receptor therapeutics comes together in its main program, SL-325, which has the potential to be a first-in-class death receptor 3 (DR3) antagonist antibody. In addition, the company is developing SL-425, a half-life extended version of SL-325, and multiple other preclinical DR3-based bispecific antibodies, for the treatment of patients with IBD.
About SHMD SCHMID Group N.V. Class A Ordinary Shares
Schmid Group NV is a global supplier of equipment, software and services for various industries such as printed circuit board (PCB), substrate manufacturing, photovoltaics, and glass and energy storage with a focus on the highest end of this market in terms of technology and performance. It focuses on a modular product portfolio of machinery to use in the manufacturing of high-end PCB equipment and semiconductor packaging devices which includes common flexible circuit fabrication techniques such as subtractive, semi-additive processes (SAP) and modified semi-additive processes (mSAP).